Tyrosine Pharma Names Laslie President and CEO
Tyrosine Pharma, Inc., has announced the appointment of Wayne Laslie as president and chief executive officer.
Investors Purchase Large Volume of Put Options on Myriad Genetics
Myriad Genetics was the recipient of unusually large options trading activity on Monday.
Myriad's invalidated patents spur LabCorp to offer competing breast cancer test
LabCorp has announced its version of a genetic test for mutations in the BRCA1 and BRCA2 genes that signal an increased risk of breast cancer.
Invitae Responds Being Names as Defendant in Myriad Genetics Lawsuit
Invitae Corporation today announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer patients through Invitae Corporation today announced that it plans to defend its right to provide naturally occurring genetic information and services to physicians for their cancer ... (more)
Biotech Site Sparks New Hope for Cancer Patients
The latest victory in the Myriad Genetics case in Australia, allowing Myriad Genetics to patent isolated DNA has sparked new debate over the development of new drugs to treat cancer.
Salt Lake Tribune
Myriad Genetics campaign encourages families to talk about hereditary cancer
It may not be the cheeriest of subjects for the holidays, but Salt Lake City's Myriad Genetics is urging families to talk about their health history this season.
Stocks to Track- Time Warner Cable Inc (NYSE:TWC), Myriad Genetics,...
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
Experts Weigh In On Gene Patents
Last summer, the United States' Supreme Court decided that patents held by Myriad Genetics over the BRCA1 and BRCA2 genes - variants of which predispose certain individuals to breast cancer - were not valid, closing at least one chapter on years of litigation involving the company.
Myriad Genetics Launches myPath Melanoma Diagnostic Test
Myriad Genetics, Inc. today announced that it has launched Myriad myPath Melanoma, a new diagnostic test to effectively differentiate malignant melanoma from benign pigmented skin lesions.